ArticleThe New England journal of medicine2020
Urate-Lowering Therapy and Chronic Kidney Disease Progression.
Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of uric acid reduction on chronic kidney disease. Systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.Scientific reports · 2022Trial
- Therapeutic potential and research progress of microecological agents in kidney diseases.Frontiers in medicine · 2026Review
- An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 2022Review
- Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights From a Population-Based, Propensity Score-Matched Analysis.Clinical pharmacology and therapeutics · 2022Article
- Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression.PloS one · 2022Article
- Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy.Diagnostics (Basel, Switzerland) · 2021Review
- The Pattern of Allopurinol Prescription Among Chronic Kidney Disease Patients in a Tertiary Care Centre: A Single-Centre Experience.International journal of general medicine · 2021Article
- The dirty little secret of urate-lowering therapy: useless to stop chronic kidney disease progression and may increase mortality.Clinical kidney journal · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32579818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.